HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rolleman, E. J. Articles by de Jong, M. Search for Related Content PubMed PubMed Citation Articles by Rolleman, E. J. Articles by de Jong, M.

Uptake of [¹¹¹In-DTPA⁰]Octreotide in the Rat Kidney Is Inhibited by Colchicine and Not by Fructose

Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

The high renal uptake of radiolabeled somatostatin analogs is dose limiting. Lowering this uptake permits higher radioactivity doses and, thus, tumor doses to be administered. We tested the effects of the microtubule drug colchicine on renal uptake of [¹¹¹In-DTPA⁰]octreotide. Also, the effects of fructose were tested. Methods: Organ radioactivity 24 h after injection of [¹¹¹In-DTPA⁰]octreotide was determined in rats. Results: Coinjection of 1 mg of colchicine per kilogram did not influence renal uptake of [¹¹¹In-DTPA⁰]octreotide, whereas this dose administered 5 h before [¹¹¹In-DTPA⁰]octreotide resulted in significant renal uptake reduction (63%). D-Lysine plus colchicine reduced the uptake by 76% (P < 0.01 vs. D-lysine alone). Liver and blood radioactivity levels were significantly elevated by colchicine. Fructose did not affect the biodistribution of [¹¹¹In-DTPA⁰]octreotide. Conclusion: Renal uptake of [¹¹¹In-DTPA⁰]octreotide is dependent on microtubule function in rats. The addition of colchicine to amino acid protocols may permit administration of higher doses, improving the therapeutic window of peptide receptor radionuclide therapy.

Key Words: peptide receptor radionuclide therapy • octreotide • colchicine • fructose • kidney

This article has been cited by other articles:

				A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Cancer Res., March 1, 2007; 67(5): 2178 - 2186. [Abstract] [Full Text] [PDF]

				G. J. Forster, E. B. Santos, P. M. Smith-Jones, P. Zanzonico, and S. M. Larson Pretargeted Radioimmunotherapy with a Single-Chain Antibody/Streptavidin Construct and Radiolabeled DOTA-Biotin: Strategies for Reduction of the Renal Dose J. Nucl. Med., January 1, 2006; 47(1): 140 - 149. [Abstract] [Full Text] [PDF]

				M. Behe, G. Kluge, W. Becker, M. Gotthardt, and T. M. Behr Use of Polyglutamic Acids to Reduce Uptake of Radiometal-Labeled Minigastrin in the Kidneys J. Nucl. Med., June 1, 2005; 46(6): 1012 - 1015. [Abstract] [Full Text] [PDF]

				R. Valkema, S. A. Pauwels, L. K. Kvols, D. J. Kwekkeboom, F. Jamar, M. de Jong, R. Barone, S. Walrand, P. P.M. Kooij, W. H. Bakker, et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate J. Nucl. Med., January 1, 2005; 46(1_suppl): 83S - 91S. [Abstract] [Full Text] [PDF]